PL2781516T3 - Nowe formy krystaliczne soli sodowej kwasu (4-{4-[5-(6-trifluorometylopirydyn-3-yloamino)-pirydyn-2-ylo]-fenylo}-cykloheksylo)-octowego - Google Patents
Nowe formy krystaliczne soli sodowej kwasu (4-{4-[5-(6-trifluorometylopirydyn-3-yloamino)-pirydyn-2-ylo]-fenylo}-cykloheksylo)-octowegoInfo
- Publication number
- PL2781516T3 PL2781516T3 PL13197714T PL13197714T PL2781516T3 PL 2781516 T3 PL2781516 T3 PL 2781516T3 PL 13197714 T PL13197714 T PL 13197714T PL 13197714 T PL13197714 T PL 13197714T PL 2781516 T3 PL2781516 T3 PL 2781516T3
- Authority
- PL
- Poland
- Prior art keywords
- pyridin
- ylamino
- trifluoromethyl
- cyclohexyl
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39088810P | 2010-10-07 | 2010-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2781516T3 true PL2781516T3 (pl) | 2017-05-31 |
Family
ID=44802409
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13197714T PL2781516T3 (pl) | 2010-10-07 | 2011-10-05 | Nowe formy krystaliczne soli sodowej kwasu (4-{4-[5-(6-trifluorometylopirydyn-3-yloamino)-pirydyn-2-ylo]-fenylo}-cykloheksylo)-octowego |
PL11770622T PL2625172T3 (pl) | 2010-10-07 | 2011-10-05 | Nowe formy krystaliczne soli sodowej kwasu (4-{4-[5-(6-trifluorometylopirydyn-3ylo-amino)-pirydyn-2-ylo]-fenylo}-cykloheksylo)-octowego |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11770622T PL2625172T3 (pl) | 2010-10-07 | 2011-10-05 | Nowe formy krystaliczne soli sodowej kwasu (4-{4-[5-(6-trifluorometylopirydyn-3ylo-amino)-pirydyn-2-ylo]-fenylo}-cykloheksylo)-octowego |
Country Status (25)
Country | Link |
---|---|
US (2) | US8829194B2 (pl) |
EP (2) | EP2625172B1 (pl) |
JP (1) | JP6093703B2 (pl) |
KR (2) | KR101900652B1 (pl) |
CN (1) | CN103153981B (pl) |
AR (1) | AR083317A1 (pl) |
AU (1) | AU2011312185B2 (pl) |
BR (1) | BR112013008355A2 (pl) |
CA (1) | CA2813736C (pl) |
CL (1) | CL2013000929A1 (pl) |
CO (1) | CO6710909A2 (pl) |
EC (1) | ECSP13012608A (pl) |
ES (2) | ES2618411T3 (pl) |
GT (1) | GT201300089A (pl) |
IL (1) | IL225532A0 (pl) |
MA (1) | MA34645B1 (pl) |
MX (1) | MX2013003835A (pl) |
NZ (1) | NZ608557A (pl) |
PE (1) | PE20140337A1 (pl) |
PL (2) | PL2781516T3 (pl) |
PT (2) | PT2625172T (pl) |
RU (1) | RU2612556C2 (pl) |
SG (1) | SG188586A1 (pl) |
TW (1) | TW201217360A (pl) |
WO (1) | WO2012047948A1 (pl) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR083317A1 (es) * | 2010-10-07 | 2013-02-13 | Novartis Ag | Forma cristalina de la sal sodica del acido (4-{4-[5-(6-trifluorometil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, composicion farmaceutica y un proceso para la elaboracion de la modificacion c |
CA2844835A1 (en) * | 2011-09-12 | 2013-03-21 | Uwe Grether | N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides |
SG11201406526WA (en) * | 2012-04-27 | 2014-11-27 | Novartis Ag | Cyclic bridgehead ether dgat1 inhibitors |
US9108956B2 (en) * | 2012-04-27 | 2015-08-18 | Novartis Ag | Cyclic ether DGAT1 inhibitorscyclic ether DGAT1 inhibitors |
WO2013169648A1 (en) * | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug |
KR101646716B1 (ko) | 2016-02-15 | 2016-08-08 | 서성환 | 조립식 나선계단용 스페이서 및 이를 이용한 조립식 나선계단 |
MX2021007544A (es) * | 2018-12-20 | 2021-08-11 | Merck Sharp & Dohme Llc | Nuevas formas cristalinas de un compuesto inhibidor de la translocacion de la transcriptasa inversa de nucleosidos. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
ATE442365T1 (de) | 2003-05-20 | 2009-09-15 | Novartis Pharma Gmbh | N-acyl stickstoffheterocyclen als liganden von peroxisom-proliferator-aktivierten rezeptoren |
US20050226906A1 (en) | 2004-04-08 | 2005-10-13 | Micro Nutrient, Llc | Nutrient system for individualized responsive dosing regimens |
ES2430115T3 (es) * | 2006-03-31 | 2013-11-19 | Novartis Ag | Inhibidor de DGAT |
WO2008073865A2 (en) * | 2006-12-11 | 2008-06-19 | Novartis Ag | Method of preventing or treating myocardial ischemia |
AR083317A1 (es) * | 2010-10-07 | 2013-02-13 | Novartis Ag | Forma cristalina de la sal sodica del acido (4-{4-[5-(6-trifluorometil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acetico, composicion farmaceutica y un proceso para la elaboracion de la modificacion c |
-
2011
- 2011-10-05 AR ARP110103699A patent/AR083317A1/es unknown
- 2011-10-05 WO PCT/US2011/054841 patent/WO2012047948A1/en active Application Filing
- 2011-10-05 JP JP2013532893A patent/JP6093703B2/ja active Active
- 2011-10-05 SG SG2013019906A patent/SG188586A1/en unknown
- 2011-10-05 PT PT117706226T patent/PT2625172T/pt unknown
- 2011-10-05 EP EP11770622.6A patent/EP2625172B1/en active Active
- 2011-10-05 EP EP13197714.2A patent/EP2781516B1/en active Active
- 2011-10-05 ES ES11770622.6T patent/ES2618411T3/es active Active
- 2011-10-05 US US13/876,063 patent/US8829194B2/en active Active
- 2011-10-05 PE PE2013000799A patent/PE20140337A1/es not_active Application Discontinuation
- 2011-10-05 PL PL13197714T patent/PL2781516T3/pl unknown
- 2011-10-05 KR KR1020187001729A patent/KR101900652B1/ko active IP Right Grant
- 2011-10-05 NZ NZ608557A patent/NZ608557A/en not_active IP Right Cessation
- 2011-10-05 KR KR1020137011696A patent/KR20130115277A/ko not_active Application Discontinuation
- 2011-10-05 MX MX2013003835A patent/MX2013003835A/es active IP Right Grant
- 2011-10-05 RU RU2013120549A patent/RU2612556C2/ru active
- 2011-10-05 ES ES13197714.2T patent/ES2618426T3/es active Active
- 2011-10-05 BR BR112013008355A patent/BR112013008355A2/pt not_active IP Right Cessation
- 2011-10-05 PL PL11770622T patent/PL2625172T3/pl unknown
- 2011-10-05 PT PT131977142T patent/PT2781516T/pt unknown
- 2011-10-05 AU AU2011312185A patent/AU2011312185B2/en active Active
- 2011-10-05 CN CN201180048559.6A patent/CN103153981B/zh active Active
- 2011-10-05 CA CA2813736A patent/CA2813736C/en active Active
- 2011-10-06 TW TW100136327A patent/TW201217360A/zh unknown
-
2013
- 2013-04-02 IL IL225532A patent/IL225532A0/en unknown
- 2013-04-04 GT GT201300089A patent/GT201300089A/es unknown
- 2013-04-05 CL CL2013000929A patent/CL2013000929A1/es unknown
- 2013-04-08 CO CO13090547A patent/CO6710909A2/es unknown
- 2013-05-03 MA MA35870A patent/MA34645B1/fr unknown
- 2013-05-07 EC ECSP13012608 patent/ECSP13012608A/es unknown
-
2014
- 2014-07-31 US US14/448,011 patent/US20140343102A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL225532A0 (en) | New crystalline forms of the sodium salt of (4-{4-[5-(6-trifluoromethyl-pyridine-3-ylamino)-pyridine-2-yl]phenyl}-cyclohexyl)-acetic acid | |
IL295518B1 (en) | Heterocyclic compounds used as pdk1 inhibitors | |
SMT201600174B (it) | Forme solide di acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]diossol-5-il)ciclopropancarbossammido)-3-metilpiridin-2-il)benzoico | |
EP2327697A4 (en) | N-Ý4- (1-CYANOCYCLOPENTYL) PHENYL-2- (4-PYRIDYLMETHYL) AMINO-3-PYRIDINECARBOXAMIDE SALTS | |
HK1183014A1 (en) | Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide 6--3--2- | |
PL2455379T3 (pl) | Kryształy soli sodowych pirolochinolinochinonu | |
IL222348A0 (en) | Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate | |
HK1202237A1 (zh) | -二氯- -苯並 咪唑- -基 -吡唑- -羧酸的葡甲胺鹽製劑 | |
HK1192558A1 (zh) | 取代的 噻唑- -羰基 -或者 噻唑- -羰基 -氨基丙酸衍生物及其作為藥物的用途 | |
EP2535342A4 (en) | SALT OF CONDENSED HETEROCYCLIC DERIVATIVE AND CRYSTAL THEREOF | |
HK1164297A1 (en) | Preparation of 1-(substituted aryl)-5-trifluoromethyl-2-(1h)-pyridone compounds and salts thereof and their applications 1-()-5--2-(1h) | |
ZA201400474B (en) | A crystalline form of the sodium salt of 4-tert-butyl-n-[chloro-2-(1-oxy-pyridine-4-carbonyl)phenyl]-benzene sulfonamide | |
PL2582240T3 (pl) | Chwastobójcza kompozycja soli kwasu pikolinowego | |
IL209836A0 (en) | Carboxylic acid salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine | |
IL209837A0 (en) | Sulfonate salts of flupirtine | |
IL214517A0 (en) | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
IL225680A0 (en) | Process for preparing 3-(6-amino-pyridin-3-yl)2-acrylic acid derivatives | |
PL2943488T3 (pl) | Postacie soli megluminowej kwasu 2-((1r,4r)-4-(4-(5-(benzoksazol-2-iloamino)pirydyn-2-ylo)fenylo)cykloheksylo)octowego i ich zastosowania jako inhibitory dgat1 | |
TN2013000136A1 (en) | New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl] -phenyl} - cyclohexyl) -acetic acid |